The researchers are developing a potential
new immunotherapy strategy for melanoma based on their insights into Autoimmune Polyendocrinopathy Type 1, a rare, inherited disorder in which T - cells attack healthy cells and tissues.
Not exact matches
«Discovery opens door to
new strategy for cancer
immunotherapy.»
«Our research sheds light on the mechanism of this impairment, pointing us in the direction of
new strategies for improving the response to
immunotherapy.»
«Our results in experimental models of cancer suggest a
new therapeutic
strategy based on inhibiting the microRNA machinery — or the Let - 7 microRNAs — specifically in the TAMs, which may unleash the power of mainstream
immunotherapies, such as immune checkpoint inhibitors.»
Immunotherapies are a promising
new strategy to fight multiple myeloma.
CRI provides a pilot grant to Jean - Pierre Mach for preclinical studies to test a
new cancer
immunotherapy strategy using anti-tumor antibody fragments conjugated to antigenic MHC / peptide complexes.
«Insights derived from these data will be critical to improving the effectiveness of current cancer
immunotherapy treatments and developing
new immune - based treatment
strategies,» said Justin Guinney, Ph.D., principal investigator, director of computational oncology and bioinformatics at Sage Bionetworks.
A novel approach to cancer
immunotherapy —
strategies designed to induce the immune system to attack cancer cells — may provide a
new and cost - effective weapon against some of the most deadly tumors, including ovarian cancer and mesothelioma.